Literature DB >> 17673480

Lymphopenia is associated with neuropsychiatric manifestations and disease activity in paediatric systemic lupus erythematosus patients.

H-H Yu1, L-C Wang, J-H Lee, C-C Lee, Y-H Yang, B-L Chiang.   

Abstract

OBJECTIVES: To investigate if lymphopenia is associated with clinical manifestations, disease activity and prognosis in systemic lupus erythematosus (SLE).
METHODS: The charts of 186 paediatric patients with SLE diagnosed between 1985 and 2006 in a medical centre were retrospectively reviewed. Lymphocyte counts were recorded at the time of SLE diagnosis and SLE flares. Global disease activity was quantified by the SLE Disease Activity Index (SLEDAI). Cumulative organ damage was assessed by the ACR/Systemic Lupus International Collaborating Clinics (SLICC) damage index.
RESULTS: Lymphopenia (<1500/mm(3)) and marked lymphopenia (<500/mm(3)) was observed in 62.8 and 12.2% at the time of SLE diagnosis. At the time of SLE diagnosis, lymphopenia was significantly associated with oral ulcers, leucopenia, anti-dsDNA antibodies and C4 decrease. At the time of flares, lymphopenia was significantly associated with anti-dsDNA antibodies, methylprednisolone pulse therapy, disease activity and organ damage. Using multivariate logistic regression, marked lymphopenia was independently associated with neuropsychiatric manifestations [odds ratio (OR) 7.41, 95% confidence interval (CI) 1.99-27.0], and protective from LN (OR 0.13, 95% CI 0.03-0.53).
CONCLUSIONS: Lymphopenia at SLE flares is associated with disease activity and organ damage. Marked lymphopenia is independently associated with neuropsychiatric manifestations.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17673480     DOI: 10.1093/rheumatology/kem182

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  10 in total

1.  Variation in protein levels obtained from human blood cells and biofluids for platelet, peripheral blood mononuclear cell, plasma, urine and saliva proteomics.

Authors:  L Katie Crosley; Susan J Duthie; Abigael C Polley; Freek G Bouwman; Carolin Heim; Francis Mulholland; Graham Horgan; Ian T Johnson; Edwin C Mariman; Ruan M Elliott; Hannelore Daniel; Baukje de Roos
Journal:  Genes Nutr       Date:  2009-04-29       Impact factor: 5.523

Review 2.  Autoantibodies involved in neuropsychiatric manifestations associated with systemic lupus erythematosus: a systematic review.

Authors:  Savino Sciascia; Maria Laura Bertolaccini; Dario Roccatello; Munther A Khamashta; Giovanni Sanna
Journal:  J Neurol       Date:  2014-06-21       Impact factor: 4.849

3.  Pediatric lupus--are there differences in presentation, genetics, response to therapy, and damage accrual compared with adult lupus?

Authors:  Rina Mina; Hermine I Brunner
Journal:  Rheum Dis Clin North Am       Date:  2010-02       Impact factor: 2.670

4.  Depression with psychotic features in a child with SLE: successful therapy with psychotropic medications--case report.

Authors:  Milica Pejovic Milovancevic; Vladimir Miletic; Smiljka Popovic Deusic; Saveta Draganic Gajic; Dusica Lecic Tosevski
Journal:  Eur Child Adolesc Psychiatry       Date:  2012-10-10       Impact factor: 4.785

Review 5.  Biomarkers for CNS involvement in pediatric lupus.

Authors:  Tamar B Rubinstein; Chaim Putterman; Beatrice Goilav
Journal:  Biomark Med       Date:  2015       Impact factor: 2.851

6.  Active systemic lupus erythematosus is associated with failure of antigen-presenting cells to express programmed death ligand-1.

Authors:  N Mozaffarian; A E Wiedeman; A M Stevens
Journal:  Rheumatology (Oxford)       Date:  2008-07-23       Impact factor: 7.580

7.  Differential manifestations of prepubescent, pubescent and postpubescent pediatric patients with systemic lupus erythematosus: A retrospective study of 96 Chinese children and adolescents.

Authors:  Li-Lan Chiang; Yu-Tsan Lin; Hung-Yi Chan; Bor-Luen Chiang
Journal:  Pediatr Rheumatol Online J       Date:  2012-05-02       Impact factor: 3.054

8.  B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels.

Authors:  Mark N Lazarus; Tabitha Turner-Stokes; Konstantia-Maria Chavele; David A Isenberg; Michael R Ehrenstein
Journal:  Rheumatology (Oxford)       Date:  2012-02-15       Impact factor: 7.580

9.  Antilymphocyte antibodies in systemic lupus erythematosus: association with disease activity and lymphopenia.

Authors:  Chun Li; Rong Mu; Xiao-yan Lu; Jing He; Ru-lin Jia; Zhan-guo Li
Journal:  J Immunol Res       Date:  2014-04-17       Impact factor: 4.818

10.  [Frequency, clinical implication and prognostic value of lymphopenia in systemic lupus erythematosus: case-control study].

Authors:  Fatima Zahra Ha-ou-nou; Lamiaa Essaadouni
Journal:  Pan Afr Med J       Date:  2015-05-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.